Compare Crown Castle International Corp (CCI) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crown Castle International Corp vs Johnson & Johnson — how do they compare? Crown Castle International Corp trades at $73.8 (market cap $31.33B), while Johnson & Johnson trades at $257.66 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 20× Crown Castle International Corp's market cap, and Crown Castle International Corp pays the higher dividend (5.77%). Which is the better fit depends on your goals.
| CCI | JNJ | |
|---|---|---|
Market Cap | $31.33B | $626.09B |
Sector | Real Estate | Health |
52-Week High | $103.79 | $267.24 |
52-Week Low | $73.61 | $172.78 |
Enterprise Value | $53.69B | $654.37B |
Dividend Yield | 5.77% | 2.06% |
Volume | — | 6,156,228 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crown Castle (CCI) trades at $73.61, down 2.62% on the day and near 52-week lows. The technical picture is bearish with mixed fundamentals - strong profitability margins (73.7% gross margin) but negative shareholder equity and high debt levels. Recent Q2 2026 earnings beat expectations with AFFO of $1.13 per share, while the company transitions to a pure-play U.S. tower operator following asset sales.
The stock presents a contrarian opportunity with 50% analyst buy ratings and a $95.29 price target suggesting 29% upside, but faces significant debt burden and execution risks from strategic shifts. The 5.5% dividend yield provides income support while investors await operational improvements.
Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.
The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
